<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="178">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01251159</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000688223</org_study_id>
    <secondary_id>ECOG-E1900T4</secondary_id>
    <nct_id>NCT01251159</nct_id>
  </id_info>
  <brief_title>Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Somatic Mutations in Stem and Progenitor Cells in AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>Unspecified</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may
      help doctors learn more about changes that occur in DNA and identify biomarkers related to
      cancer.

      PURPOSE: This laboratory study is studying bone marrow samples from patients with acute
      myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To rigorously examine fractionated hematopoietic stem and progenitor cells from
           patients with acute myeloid leukemia (AML).

        -  To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA,
           NPM1, TET2, ASXL1, IDH1, and IDH2 mutations.

        -  To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the
           selected mutations and in what order those mutations occur.

      OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of
      mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the
      results of age-matched healthy controls.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Define somatic mutations occurring in de novo AML</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Selected mutations and order occurrence</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of  antecedent clonal subpopulations with AML mutations that occur earlier in pathogenesis but not in later pathogenesis</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia

          -  Bone marrow samples must meet 1 of the following criteria:

               -  Normal karyotype from patients enrolled on ECOG-1900 archived at the ECOG
                  Leukemia Tissue Bank

                    -  Live, sortable mononuclear cells prepared at the time of initial diagnosis
                       (slow-frozen in media with 10% DMSO OR fresh cells shipped immediately

               -  Age-matched healthy control samples from commercial providers

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich G. Steidl, MD, BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine of Yeshiva University</affiliation>
  </overall_official>
  <link>
    <url>http://cancer.gov/clinicaltrials/ECOG-E1900T4</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQÂ® database</description>
  </link>
  <verification_date>November 2010</verification_date>
  <lastchanged_date>November 30, 2010</lastchanged_date>
  <firstreceived_date>November 30, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Robert L. Comis</name_title>
    <organization>ECOG Group Chair's Office</organization>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with del(5q)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
</clinical_study>
